MPLX heads into the back half of August with fresh analyst tailwinds and options positioning that has tilted decisively toward calls — the most bullish lean the derivatives market has shown in months.
The standout this week is Morgan Stanley's target revision. Robert Kad raised his price target from $60 to $66 on August 12, maintaining Equal-Weight — a meaningful $6 lift that now places Morgan Stanley's target well above the current consensus mean of $61.92. That follows Barclays raising to $63 from $59 on August 6, and Wells Fargo's post-Q2 bump to $63 from $61 on August 5. Three firms lifting targets inside a week points to the same thing: the Q2 print — reported August 4 — was clean enough to prompt genuine upward revisions, not just housekeeping. The stock has pulled back 2% on the week to $59.30, a modest give-back from the post-earnings bounce, creating a modest gap between current price and where the Street is moving its targets.
Options traders are leaning the same direction. The put/call ratio has dropped to 0.30, more than one and a half standard deviations below its 20-day average of 0.39 — the lowest call-dominant reading in nearly a year, with the 52-week low sitting at 0.18. That is a sharp contrast to where PCR was running in mid-July, when it touched 0.52 and the mood around the stock was noticeably more cautious. The shift toward calls has accelerated since the earnings print, reinforcing what the analyst moves are saying: the post-Q2 narrative has turned constructive.
Short interest at 0.76% of the free float is too thin to drive the story in either direction. It has crept up about 10% over the past week in share-count terms — from roughly 7.0 million to 7.7 million — but at this level the absolute position remains trivial. The borrow market reflects that: cost to borrow has fallen sharply, dropping more than 20% on the week to just 0.23%. Availability is exceptionally loose at over 500%, meaning there is roughly five times more stock available to borrow than is currently borrowed. The lending market is not telling a squeeze story; it is telling a story of indifference.
The broader bull case, as laid out by analysts, rests on several infrastructure completions in the second half of 2026 — the Titan Processing complex, Blackcomb and Bay Runner Pipelines, and continued Permian expansion — alongside fee-based cash flows that insulate earnings from commodity-price swings. The dividend score ranks in the 99th percentile, a reflection of the yield-focused ownership base; ALPS Advisors, Invesco, and specialist midstream names like Tortoise Capital and Harvest Fund Advisors collectively hold meaningful positions. Marathon Petroleum remains the dominant unit-holder at 63.8% of shares, a structural anchor that limits takeover optionality — the bear case from Wolfe Research's late-July downgrade to Peer Perform rested partly on that same point. Against close peers, the contrast is modest but notable: ET gained 2.2% on the week and AM added 1.1%, while MPLX slipped — suggesting the week's drift lower reflects position trimming after the earnings pop rather than any fundamental deterioration.
With the next earnings event not until November 3, the near-term watch is whether the Morgan Stanley target lift triggers further consensus movement and whether call positioning sustains its current lean as more of the H2 infrastructure pipeline comes into view.
See the live data behind this article on ORTEX.
Open MPLX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
